www.forbes.com/sites/matthewherper/2017/...ults/#490663642b32
www.fool.com/investing/2017/09/12/...stock-a-bad-news-bu.aspx
|
PDUFA Extension for ZULRESSO™ (brexanolone) Injection
"The previously disclosed December 19, 2018 PDUFA goal date has been extended by a period of three months to March 19, 2019."
investor.sagerx.com/news-releases/...fication-pdufa-extension
Shelf Offering
www.sec.gov/Archives/edgar/data/1597553/.../d674515ds3asr.htm
positive SAGE-217 Studienergebnisse
www.statnews.com/2019/01/07/...ion-in-pivotal-clinical-trial/
Public Offering
investor.sagerx.com/news-releases/...-offering-common-stock-1
FDA Zulassung für Zulresso (PPD)
www.pharmaceutical-business-review.com/...epression-zulresso/
Phase3 Studie SAGE-217 verfehlt primären Endpunkt
investor.sagerx.com/news-releases/...-results-pivotal-phase-3
Zahlen für 2019
investor.sagerx.com/news-releases/...arter-and-full-year-2019
www.fool.com/investing/2020/02/27/...-with-its-q4-report.aspx
Restruktuierung
investor.sagerx.com/news-releases/...turing-advance-corporate
Gut aufgepasst, es handelt sich um einen Tippfehler! Hier der Originalwortlaut:
"Current balance of cash, cash equivalents, restricted cash, and marketable securities expected to support operations into 2022"
Zahlen für Q3/20
Ongoing zuranolone Phase 3 pivotal trials in major depression and postpartum depression progressing well; expect to initiate dosing in CORAL Study in 4Q 2020
investor.sagerx.com/news-releases/...r-2020-financial-results
globale Kollaboration mit Biogen (in MDD)
investor.sagerx.com/news-releases/...nce-global-collaboration
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
69 | SAGE 63,30$ | Vassago | Vassago | 07.04.24 17:06 |